Search Results

Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to its Board of Directors of Dr. Theresa Heah.

Dr. Brandon Charles has joined Curative as its new Chief Medical Officer.

Curative Biotechnology Inc. today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann.

Curative Insurance Company, a pioneering healthcare services company, and GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members.

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, Excision BioTherapeutics’ HIV gene editor failed to suppress viral activity.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent.

Curative Biotechnology Inc. announced that a Patent Cooperation Treaty application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25, 2022.

Long-time liver specialist Carrie Frenette says she won’t ever forget the people she treated for hepatitis C (HCV) before 2013 - the year that the Food and Drug Administration (FDA) approved a Gilead medicine.

Curative Biotechnology Inc., a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset licensing within the country.

As Vertex and CRISPR Therapeutics’ exa-cel and Verve Therapeutics’ VERVE-101 move forward, questions remain about possible drawbacks of such therapies.